Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma
Introduction
Lung cancer is the most frequent cancer and cause of cancer death in men and women combined[1], [2]. In women, it is the third most common cancer type (770 828 new cases in 2020) and the second most common cause of cancer death[1], [2]. In France, the incidence and mortality of lung cancer rose by 5.3% and 3.5%, respectively, for women between 1998 and 2010, and it was responsible for 10 356 deaths in 2018[4]. Because of the smoking epidemic in women, most countries are observing an increasing incidence of lung cancer in women particularly in developing countries[1], [2]. While the majority of lung cancers are associated with tobacco smoking, the World Health Organization estimates that 25% of lung cancer worldwide occurs in never smokers[5]. This percentage is probably closer to 10–15% in Western countries, and varies widely from approximately 2–6% in men in Western series to more than 50% in women from Southeast Asia[5].
Overall, the estimated incidence of any cancer during pregnancy is 1/1000 pregnancies[6]. In France, while the exact incidence of lung cancers associated with pregnancy is unknown, it is estimated at around 3.5% by the French national network, Cancer Associé à La Grossesse (CALG)[6]. Lung cancer associated with pregnancy is a rare event but on the increase both because more young women are smoking and women are delaying having children till later in life[7], [8]. Lung cancers are also more frequently observed in women non-smokers than men non-smokers [9], [10]. Almost all are of the adenocarcinoma subtypes compared to NSCLC in smokers and appear to be a distinct disease caused by oncogenic drivers[9], [10], [11]. The two main known oncogenic drivers are EGFR (Epidermal Growth Factor Receptor) mutations and ALK (Anaplastic Lymphoma Kinase) fusions present, respectively, in 10 to 20% (up to 40% in Asians), and 2 to 7% of NSCLC in Caucasians and Asians [12]. EGFR mutations are more frequent in women while ALK fusions are more frequent in young patients[9], [10], [12]. Many small molecule kinase inhibitors have been developed to target these molecular alterations[12]. They now represent the first-line treatment for advanced stage NSCLC with oncogenic driver increasing overall survival compared with the standard platinum-based doublet chemotherapy[12].
During pregnancy, most lung cancers are diagnosed at advanced stage raising a major medical challenge about how to best manage the maternal disease while limiting the impact on fetal outcomes[6], [7], [8]. While considerable data have been accumulated regarding the use of chemotherapy during pregnancy, little is known about the use of small molecule kinase inhibitors in such a setting[13]. Therefore, the aim of the current study was to describe the oncological and obstetric outcomes of patients diagnosed with oncogenic-driven advanced NSCLC treated by kinase inhibitors during pregnancy and especially authorized ALK/EGFR tyrosine kinase inhibitors (TKI) using the prospective database of the CALG network.
We queried the prospective database of the CALG network (Tenon Hospital, Sorbonne University, Paris, France) with the term “pregnant patients with lung cancer receiving a kinase inhibitor”. The CALG network was established in 2008 to investigate oncological and obstetric care, and maternal and neonatal outcomes in women with a cancer associated with pregnancy. The CALG database collects cases of cancers associated with pregnancy or diagnosed during the first postpartum year. All patients received clear and complete information and gave their consent. The Ethics Committee (CEROG) of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) approved the study (CEROG-2019-GYN-603).
Patients diagnosed with a lung cancer associated with pregnancy between January 2011 and September 2020, and for whom advice was requested from the CALG network, were eligible for participation. Subsequently, only patients who received a TKI during pregnancy were analyzed. Exclusion criteria were patients with lung cancer associated with pregnancy not receiving a TKI and patients diagnosed with lung cancer during the first postpartum year.
Lung cancer diagnosis was systematically proven by histology. The following data were recorded: age, parity at diagnosis, smoking, familial and personal history of cancer, obstetric history, term at diagnosis, exams performed during pregnancy, lung cancer disease stage using the 8th edition of the lung cancer TNM staging, pathological and molecular features of the cancer, treatment regimen received during the pregnancy and in the postpartum period, term and mode of delivery, and neonatal and maternal outcomes. Maternal as well umbilical cord blood plasma concentrations of TKIs were reported if available. The clinical status of patients and children were updated in April 2021.
We used the methodology recommended by the Prisma statement for reviews and meta-analyses. The literature research was conducted in Medline, Embase and the Cochrane Library and was limited to studies published in English and French between January 2000 and April 2021. The MeSH Database of Pubmed helped steer the search by combining the following MeSH keywords: ‘‘lung cancer’’, ‘‘women’’, ‘‘pregnancy’’ and ‘‘tyrosine kinase Inhibitor’’, “kinase inhibitor”, “afatinib”, “alectinib”, “dacomitinib”, “brigatinib”, “dabrafenib”, “ceretinib”, “crizotinib”, “erlotinib”, “gefitinib”, “lorlatinib”, “osimertinib” and “vemurafenib” Fig. 1. Only original studies reporting pregnant patients treated by a market authorized TKI for lung cancer were retained. Other studies were not analyzed (Supplementary data).
Section snippets
Results
Between 2011 and 2020, 540 patients were registered for a cancer associated with pregnancy in the CALG network including 17 patients (3.1%) with lung cancer. Among the patients with lung cancer diagnosed during pregnancy, three patients received an ALK- or EGFR-TKI (Table 1).
Discussion
Chemotherapy remains the therapeutic standard of care for most patients with advanced NSCLC without an oncogenic driver, even in the era of immunotherapy but is contraindicated during the first trimester of pregnancy due to teratogenic effects[13]. Recent developments have given rise to various authorized targeted therapies including EGFR-TKI (gefitinib, erlotinib, afatinib, dacomitinib, osimertinib) and ALK-TKI (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib) for oncogenic-driven
Conclusion
Lung cancer during pregnancy is a rare event but its incidence is on the increase. Each patient should be considered separately, and the maternal benefits weighed against fetal risks. The 11 cases reported here support the rationale of the use of TKIs rather than chemotherapy in the setting of oncogenic-driven advanced NSCLC both in terms of maternal disease effectiveness and the relatively mild effects on the fetus. Further case series are required to describe experiences of the use of TKIs
CRediT authorship contribution statement
Anne-Sophie Boudy: Conceptualization, Methodology, Validation, Investigation, Resources, Data curation, Writing – original draft. Noémie Grausz: Conceptualization, Data curation, Writing – original draft. Lise Selleret: Resources, Data curation. Joseph Gligorov: Validation, Resources. Isabelle Thomassin-Naggara: Validation, Data curation. Cyril Touboul: Conceptualization, Resources, Data curation. Emile Daraï: Conceptualization, Methodology, Validation, Investigation, Resources, Data curation,
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
We would like to thank Elefant Elisabeth (Centre de Référence sur les Agents Tératogènes, APHP, Sorbonne University, Paris, France), Doucet Ludovic (Hôpital Saint-Louis, service d’oncologie médicale, APHP, Paris, France) and Blanchet Benoit (Groupe de Pharmacologie Clinique Oncologique (GPCO), Paris, France) for their participation in this research.
Bibliography (44)
- et al.
Lung cancer in never smokers–a review
Eur J Cancer.
(2012) - et al.
Lung cancer in never smokers: change of a mindset in the molecular era
Lung Cancer.
(2011) - et al.
Molecular genetics of lung cancer in people who have never smoked
Lancet Oncol.
(2008) - et al.
Lung cancer: current therapies and new targeted treatments
Lancet.
(2017) - et al.
Breast cancer in pregnancy
Lancet.
(2012) - et al.
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy
Lung Cancer.
(2008) - et al.
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure
Lung Cancer.
(2011) - et al.
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma
Lung Cancer.
(2012) - et al.
Efficacy and safety of gefitinib during pregnancy: case report and literature review
Lung Cancer.
(2014) - et al.
Lung cancer in pregnancy - Report of a case treated with crizotinib
Pulmonology
(2018)
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report
J Thorac Oncol.
Lung cancer during pregnancy: an unusual case
Rev Port Pneumol.
Lung cancer and pregnancy
Lung Cancer.
Characterization of the expression of the ALK receptor tyrosine kinase in mice
Gene Expr Patterns.
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model
Ann Oncol.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
CA Cancer J Clin.
Global cancer statistics, 2012
CA Cancer J Clin.
Oncological management of pregnancy-associated cancers: analysis from the French CALG (Cancer Associé à La Grossesse) network
Acta Oncol.
Increasing incidence of pregnancy-associated breast cancer in Sweden
Obstet Gynecol.
First births to older women continue to rise
NCHS Data Brief.
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
Cancer.
Cited by (8)
Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy
2024, Journal of Thoracic OncologySecond-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report
2023, Journal of Gynecology Obstetrics and Human ReproductionCardiac tamponade during pregnancy due to primary lung cancer: A case report
2023, Obstetric MedicineClinical Features and Management of Lung Cancer During Pregnancy: A Narrative Review Based on Reported Cases
2023, Women's Health Reports
- 1
Equal contribution.